Chemotherapy Response in Lung Cancer: Similar Outcomes for Partial Response and Stable Disease
Author Information
Author(s): He Lijie, Teng Yuee, Jin Bo, Zhao Mingfang, Yu Ping, Hu Xuejun, Zhang Jingdong, Li Songbai, Gao Yaling, Liu Yunpeng
Primary Institution: The First Hospital, China Medical University
Hypothesis
Does stable disease indicate similar survival outcomes as partial response in advanced non-small cell lung cancer patients after chemotherapy?
Conclusion
Patients with initial partial response and stable disease have similar progression-free survival and overall survival rates.
Supporting Evidence
- Median progression-free survival was 249 days for partial response and 220 days for stable disease.
- Median overall survival was 364 days for partial response and 350 days for stable disease.
- Patients with stable disease showed similar outcomes to those with partial response in terms of survival.
Takeaway
This study found that patients with stable disease after chemotherapy do just as well as those with a partial response, meaning both groups can expect similar survival times.
Methodology
The study included 179 advanced NSCLC patients and compared progression-free survival and overall survival between those with initial partial response and stable disease after two courses of chemotherapy.
Limitations
The study is based solely on tumor size and does not account for tumor viability or other factors that may affect survival.
Participant Demographics
{"median_age":57,"age_range":"26-77","sex_distribution":{"male":60,"female":40},"stage_distribution":{"stage_IIIB":57,"stage_IV":97},"weight_loss":{"≥5%":42,"<5%":58}}
Statistical Information
Confidence Interval
{"pfs":"95% CI, 187-310 days for PR; 95% CI, 191-248 days for SD","os":"95% CI, 275-452 days for PR; 95% CI, 293-406 days for SD"}
Statistical Significance
p > 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website